Moving To An Allogeneic RNA Cell Therapy Program With Cartesian Therapeutics' Dr. Metin Kurtoglu
Source: Applied Biosystems by Thermo Fisher Scientific, qPCR
![22_01_cgpodcast_1200x628_ep24 22_01_cgpodcast_1200x628_ep24](https://vertassets.blob.core.windows.net/image/cf166b8d/cf166b8d-3f81-4357-81a4-90a392adfcd6/375_250-22_01_cgpodcast_1200x628_ep24.png)
Dr. Metin Kurtoglu, COO at Cartesian Therapeutics, explains the clinical-stage biotech's autologous RNA cell therapies, Descartes-08 for Myasthenia Gravis and Descartes-11 for multiple myeloma. He also explains Descartes-25, their allogeneic RNA cell therapy and the reasons for the move to "off-the-shelf," and why the future of RNA cell therapy is not confined to rare and fatal diseases. We also discuss post-care for patients having received infusions.
access the Podcast!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Applied Biosystems by Thermo Fisher Scientific, qPCR
This website uses cookies to ensure you get the best experience on our website. Learn more